Summary
Alzheimer’s disease is a devastating illness that will become more common as the population ages. Although clinical diagnosis of the illness is not certain without histological examination of the brain, and misdiagnosis may occur, broad working criteria to help diagnose the likely presence of Alzheimer’s disease are available. Thoughtful clinical evaluation improves diagnostic accuracy, and appropriately diagnosed patients are critical for involvement in research into new antidementia agents.
Essential to the discovery of new drugs is careful measurement of illness response. A variety of scales — some aimed at patients, others at their caregivers, and yet others for clinicians — assess Alzheimer’s disease severity, progression, symptom response, and quality of life. Of note, patient response is not the only measurement of treatment benefit today. Growing interest is also being placed on tracking the possible amelioration of caregiver ‘burden’. This burden refers to the psychological, physical, and material costs of providing care for an Alzheimer’s patient over long periods of time. A number of scales and questionnaires have been developed and are occasionally used.
Many drugs have been tried in Alzheimer’s disease, but very few have produced any benefit, and this is often modest. Ergoloid mesylates, initially thought to be effective, are now considered of little value. The cholinomimetic drugs, especially the acetylcholinesterase inhibitor tacrine, have provided a very modest benefit, slowing the progression of the illness for a number of months. No cognitive improvement has been noted with the various nootropic agents such as piracetam. Early studies with levacecarnine (acetyl-L-carnitine), a substance that facilitates the use of fatty acids, memantidine, the dimethyl derivative of amantidine, and the calcium channel blocker nimodipine, have shown some promise, but require larger, more rigorous studies.
As mentioned above, documenting effects in individual patients is crucial; examining for potential benefit to caregivers is a growing part of research design. Current treatment efforts will become more sophisticated as a deeper understanding of the neurobiology of Alzheimer’s disease develops. For the immediate future, the goal is not cure but slowing of the disease process. Achieving this limited goal would have a substantial impact on the financial and human costs of the illness.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Anonymous. Dementia — the quiet epidemic [editorial]. BMJ 1978; 1: 1–2
Clarfield AM. The reversible dementias: do they reverse? Ann Intern Med 1988; 109: 476–86
Perry RH, Irving D, Blessed G, et al. Dementia in old age: identification of a clinically and pathologically distinct disease category. Adv Neurol 1990; 51: 41–6
Moseley I. Imaging the adult brain. J Neurol Neurosurg Psychiatry 1995; 58: 7–21
McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44
Leonard B, Morris JC. Diagnosis. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer’s disease. New York: Raven Press, 1994: 1–26
American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders, 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
World Health Organization. The ICD-10 classification of mental and behavioral disorders; clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992: 45–9
Tinter RJ, Weiner MF, Bonte FJ. The dementia workup. In: Weiner MF, editor. The dementias: diagnosis and management. Washington, DC: American Psychiatric Press, Inc., 1991: 47–75
Cummings JL, Benson DF, editors. Dementia: a clinical approach. 2nd ed. Boston: Butterworth-Heinemann, 1992
Emery VOB, Oxman TE, editors. Dementia: presentation, differential diagnosis, and nosology. Baltimore: Johns Hopkins University Press, 1994
Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98
Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 1975; 23: 433–41
Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797–811
Storandt M, Botwinick J, Danziger WL, et al. Psychometric differentiation of mild senile dementia of the Alzheimer type. Arch Neurol 1984; 41: 497–9
Eslinger PJ, Damasio AR, Benton AL, et al. Neuropsychologic detection of abnormal mental decline in older persons. JAMA 1985; 253: 670–4
Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general purpose psychogeriatric rating scale. Gerontology 1983; 29: 185–8
Hollister LE, Yesavage J. Ergoloid mesylates for senile dementia: unanswered questions. Ann Intern Med 1984; 100: 894–8
Rose WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64
Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–39
Hughes CP, Berg L, Danziger WL. A clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 556–72
Dejong R, Osterland OW, Roy GW. Measurement of quality-of-life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11: 545–54
Knopfman DS, Knapp MJ, Gracon SI, et al. The Clinician Interview Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994; 44: 2315–21
Clinical Global Assessment scale (CGI). In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): US Dept of Health Education and Welfare, National Institute of Mental Health, 1976: 218–22
Lawton MP, Brody EM. Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist 1969; 9: 176–86
Spiegel R, Brunner C, Ermini-Funfschilling D, et al. A new behavioral assessment scale for geriatric out-and in-patients: the NOSGER (Nurses’ Observation Scale for Geriatric Patients). J Am Geriatr Soc 1991 Apr; 39(4): 339–47
Dippel RL. The caregivers. In: Dippel RL, Hutton JT, editors. Caring for the Alzheimer’s patient: a practical guide. 2nd ed. Buffalo: Prometheus Books, 1991: 17
Zarit SH, Ory NK, Zarit JM. The hidden victims of Alzheimer’s disease: families under stress. New York: York University Press, 1985
Elliot GR, Eisdorfer C, editors. Stress and human health. New York: Springer Verlag, 1982
Haley E, Levine EG, Brown SL, et al. Stress, appraisal, coping, and social support as predictors of adaptational outcome among dementia caregivers. Psychol Aging 1987; 2: 323–30
Hansen D, Hill R. Families under stress. In: Chistensen H, editor. Handbook of marriage and the family. Chicago: Rand-McNally, 1964: 782–819
Montgomery RJ, Stull DE. Borgatta EF. Measurement and the analysis of burden. Res Aging 1985; 7: 137–52
Biegal DE, Sales E, Schulz R. Theoretical perspectives on care-giving. In: Biegal DE, Sales E, Schulz R, editors. Family care-giving in chronic illness — Alzheimer’s disease, cancer, heart disease, mental illness, and stroke. Newbury Park: Sage Publications, 1991: 38–49
Beck AT, Beck RT. Screening depressed patients in family practice: a rapid technique. Postgrad Med 1972; 81–5
Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure 1977; 1: 385–401
Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139–45
Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837–44
Schulz R, Williamson GM. Health effects of caregiving: prevalence of mental and physical illness in Alzheimer’s caregivers. In: Light E, Niederehe G, Lebowita BD, editors. Stress effects on family caregivers of Alzheimer’s patients. New York: Springer Publishing Company, 1994: 38–63
Cooper J. Drug treatment of Alzheimer’s disease. Arch Intern Med 1991; 151: 245–9
Rossor MN. Management of neurological disorders: dementia. J Neurol Neurosurg Psychiatry 1994; 57: 1451–6
Pepeu G. Memory disorders: novel treatments, clinical perspective. Life Sci 1994; 55: 2189–94
Sarter M. Taking stock of cognition enhancers. Trends Pharmacol Sci 1991; 13: 456–61
Khatchaturian ZS, Phelps CH, Buckholz NS. The prospect of developing treatments for Alzheimer disease. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer’s disease. New York: Raven Press, 1994: 445–54
Pathy MSJ. The pharmacological management of cognitive impairment in the demented patient. Prog Neuropsych Biol Psychiatry 1993; 17: 515–24
Thal LJ. Clinical trials in Alzheimer disease. In: Terry RD, Katzman R, Blick KL, editors. Alzheimer’s disease. New York: Raven Press 1994: 431–44
Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994; 51: 787–98
Thompson II TL, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 1990; 323: 445–8
Whitehouse P. Treatment of Alzheimer disease. Alz Dis Assoc Disord 1991; 5 (1 Suppl.): 32S–36S
Farlow M, Gracon SI, Hershey LA, et al. for the Tacrine Study Group. A controlled trial of tacrine in Alzheimer’s disease. JAMA 1992; 268: 2523–9
Davis KL, Thal LJ, Gamzu E, et al. for The Tacrine Collaborative Study Group. A double-blind placebo-controlled study of tacrine for Alzheimer’s disease. N Engl J Med 1992; 327: 1253–9
Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 1994; 271: 985–91
Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer’s disease. Lancet 1991; 337: 989–92
Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer’s disease. Results of a Canadian double-blind, cross-over, multicenter study. N Engl J Med 1990; 322: 1272–6
Siegfried K. The efficacy of cholinergic drugs in patients with Alzheimer’s disease — focus on the aminacridines. Hum Psychopharm 1995; 10: 89–96
Spagnoli A, Lucca U, Mensco G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer disease. Neurology 1991; 41: 1726–32
Ditzler K. Efficacy and tolerability of memantine inpatients with dementia syndrome. A double-blind placebo controlled trial. Arzneimittel Forschung 1991; 41: 773–9
Tarlot PN, Sunderland T, Weingartner H, et al. Cognition effects of 1-deprenyl in Alzheimer’s disease. Psychopharmacology 1987; 91: 489–95
Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1991; 27: 1133–42
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hollister, L., Gruber, N. Drug Treatment of Alzheimer’s Disease. Drugs & Aging 8, 47–55 (1996). https://doi.org/10.2165/00002512-199608010-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-199608010-00008